Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

, MRK

Merck

$62.55

-0.09 (-0.14%)

08:07
04/21/17
04/21
08:07
04/21/17
08:07

Atara Biotherapeutics announces collaboration with Merck

Atara Biotherapeutics (ATRA) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), to evaluate Atara Bio's allogeneic Epstein-Barr virus, or EBV,-specific cytotoxic T lymphocytes, or ATA129, in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with platinum resistant or recurrent EBV-associated NPC. The Phase 1/2 trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination and is planned for initiation in 2018.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

MRK

Merck

$62.55

-0.09 (-0.14%)

  • 22

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

ATRA Atara Biotherapeutics
$18.90

0.45 (2.44%)

10/24/16
JEFF
10/24/16
INITIATION
Target $23
JEFF
Buy
Atara Biotherapeutics assumed with a Buy at Jefferies
Jefferies analyst Gena Wang assumed coverage of Atara Biotherapeutics with a Buy rating and $23 price target. The company's off-the-shelf cytotoxic T-lymphocytes technology could offer differentiated advantages, Wang contends.
11/21/16
WBLR
11/21/16
NO CHANGE
WBLR
Outperform
William Blair views Atara as 'overlooked and misunderstood'
William Blair analyst John Sonnier feels Atara Biotherapeutics, following last year's failure of a molecularly targeted pipeline candidate in a Phase II protein-energy wasting trial, has been "overlooked and misunderstood" by investors. Since the failure, the company has made "important advances with a differentiated T-cell platform," with plans to initiate two Phase III clinical trials by the end of this year, Sonnier tells investors in a research note. He believes Atara shares are fundamentally undervalued and reiterates an Outperform rating on the shares.
12/14/16
SBSH
12/14/16
NO CHANGE
Target $8
SBSH
Sell
Citi says Atara Biotherapeutics sell thesis is working
Citi analyst Yigal Nochomovitz believes his thesis on Atara Biotherapeutics is working after the company this week said it will not be able to start Phase 3 trials by the end of 2016. The analyst keeps a Sell rating on the shares with an $8 price target.
03/15/17
SBSH
03/15/17
NO CHANGE
Target $10
SBSH
Sell
Citi sees 50% downside risk in shares of Atara
Citi analyst Yigal Nochomovitz reiterates a Sell rating and $10 price target on shares of Atara Biotherapeutics following the stock's 40% rally this morning. The price target reflects 50% downside from current levels, the analyst points out. The stock rally came in the absence of new clinical data and with minimal updates on the pipeline, Nochomovitz tells investors in a research note. He continues to believe Atara's markets are relatively niche.
MRK Merck
$62.55

-0.09 (-0.14%)

04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.

TODAY'S FREE FLY STORIES

MLHR

Herman Miller

16:08
09/20/17
09/20
16:08
09/20/17
16:08
Hot Stocks
Breaking Hot Stocks news story on Herman Miller »

Herman Miller reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

STBZ

State Bank Financial

$27.79

0.45 (1.65%)

16:08
09/20/17
09/20
16:08
09/20/17
16:08
Hot Stocks
FDIC approves State Bank Financial, AloStar merger transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Hot Stocks
Herman Miller CEO says 'encouraged by the strong level of demand' »

Brian Walker, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ARCC

Ares Capital

$15.85

0.035 (0.22%)

16:07
09/20/17
09/20
16:07
09/20/17
16:07
Initiation
Ares Capital initiated  »

Ares Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

16:06
09/20/17
09/20
16:06
09/20/17
16:06
Earnings
Herman Miller sees Q2 EPS 55c-61c, consensus 56c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MLHR

Herman Miller

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Earnings
Herman Miller reports Q1 adjusted EPS 57c, consensus 57c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

MDXG

MiMedx

$12.34

-0.82 (-6.23%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
MiMedx responds to two "deceptive short seller articles" »

MiMedx Group responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LUNA

Luna Innovations

$1.64

0.05 (3.14%)

16:05
09/20/17
09/20
16:05
09/20/17
16:05
Hot Stocks
Luna Innovations announces stock repurchase program »

Luna Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$53.40

-5.2 (-8.87%)

16:03
09/20/17
09/20
16:03
09/20/17
16:03
Hot Stocks
Aerie announces FDA Advisory Committee meeting for Rhopressa 0.02% »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:57
09/20/17
09/20
15:57
09/20/17
15:57
Periodicals
Tesla working with AMD on self-driving car AI chip, CNBC says »

Tesla (TSLA) is using AMD…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

NVDA

Nvidia

$187.35

-0.2 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AMD

AMD

$13.12

0.04 (0.31%)

, TSLA

Tesla

$375.10

-9.9 (-2.57%)

15:54
09/20/17
09/20
15:54
09/20/17
15:54
Periodicals
Breaking Periodicals news story on AMD, Tesla »

Tesla working with AMD on…

AMD

AMD

$13.12

0.04 (0.31%)

TSLA

Tesla

$375.10

-9.9 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

15:50
09/20/17
09/20
15:50
09/20/17
15:50
General news
More from Yellen: »

More from Yellen: FOMC…

VIX

Volatility Index S&P 500 Options

15:40
09/20/17
09/20
15:40
09/20/17
15:40
Options
Active trading in VIX calls as players replace expiring positions »

Active trading in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/20/17
09/20
15:35
09/20/17
15:35
General news
Yellen on the FRB »

Yellen on the FRB: she is…

DMPI

DelMar Pharmaceuticals

$1.12

0.0294 (2.70%)

15:33
09/20/17
09/20
15:33
09/20/17
15:33
Syndicate
DelMar Pharmaceuticals announces $10M registered direct offering at-the-market »

DelMar Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$47.94

0.27 (0.57%)

15:30
09/20/17
09/20
15:30
09/20/17
15:30
Options
Far downside put buying in Morgan Stanley »

Far downside put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 22

    Oct

JWN

Nordstrom

$46.13

-0.09 (-0.19%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$71.38

-1.1 (-1.52%)

15:25
09/20/17
09/20
15:25
09/20/17
15:25
Options
Bunge call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
09/20/17
09/20
15:25
09/20/17
15:25
General news
More from Yellen on inflation »

More from Yellen on…

WFC

Wells Fargo

$53.95

0.591 (1.11%)

15:22
09/20/17
09/20
15:22
09/20/17
15:22
Hot Stocks
Chair Yellen calls Wells Fargo actions 'unacceptable' »

Fed Chair Janet Yellen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

15:20
09/20/17
09/20
15:20
09/20/17
15:20
General news
The FOMC dot-plot projections »

The FOMC dot-plot…

$NSD

NASDAQ Market Internals

15:17
09/20/17
09/20
15:17
09/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Recommendations
Alnylam analyst commentary  »

Alnylam price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NYE

NYSE Market Internals

15:16
09/20/17
09/20
15:16
09/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$170.00

4.17 (2.51%)

15:14
09/20/17
09/20
15:14
09/20/17
15:14
Conference/Events
Lennox management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.